Role of fusion in radiotherapy treatment planning

Seminars in Nuclear Medicine

Volumn 33, Issue 3, 2003, Pages 238-243

  Paulino, Arnold C ^a,b   Thorstad, Wade L ^a,b   Fox, Timothy ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIACETYLBIS(N 4 METHYLTHIOSEMICARBAZONE)COPPER; FLUORODEOXYGLUCOSE; METHIONINE DERIVATIVE; METHYLMETHIONINE; METIROSINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BONE METASTASIS; BRAIN CANCER; BRAIN TUMOR; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK CARCINOMA; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION BEAM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0038148709     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2003.127313     Document Type: Article

References (54)

1. Ling CC, Humm J, Larson S, et al: Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551-560, 2000
2. Tepper J: Form and function: The integration of physics and biology. Int J Radiat Oncol Biol Phys 47:547-548, 2000
3. Marks LB, Spencer DP, Bentel GB, et al: The utility of SPECT lung perfusion scans in minimizing and assessing the physiological consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 26:659-668, 1993
4. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212:803-809, 1999
5. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
6. Higashi K, Ueda Y, Seki H, et al: Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma. J Nucl Med 39:1016-1020, 1998
7. Webb WR, Gatsonis C, Zerhouni EA, et al: CT and MR in staging non-small cell bronchogenic carcinoma - Report of the Radiologic Diagnostic Oncology Group. Radiology 178:705-713, 1991
8. Dwamena BA, Sonnad SS, Angobaldo JO, et al: Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT. Radiology 213:530-536, 1999
9. Erasmus JJ, Patz EF Jr, McAdams HP, et al: Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR 168:1357-1360, 1997
10. Gupta NC, Graeber GM, Bishop HA: Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm) and large (>3 cm) lymph node lesions. Chest 117:773-778, 2000
11. Bury T, Paulus P, Dowlati A, et al: Evaluation of pleural diseases with PDG-PET imaging: Preliminary report. Thorax 52:187-189, 1997
12. Tucker R, Coel M, Ko J, et al: Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: First year's experience in a clinical center. J Clin Oncol 19:2504-2508, 2001
13. MacManus MP, Wong K, Hicks RJ, et al: Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52:351-361, 2002
14. Robertson JM, Ten Haken RK, Hazuka MB, et al: Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 7:1079-1085, 1997
15. Graham MV, Purdy JA, Emami B, et al: Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 33:993-1000, 1995
16. Armstrong J, Raben A, Zelefsky M, et al: Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 44:17-22, 1997
17. 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19:167-177, 1998
18. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44:593-597, 1999
19. Erdi YE, Rosenzweig K, Erdi AK, et al: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60, 2002
20. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55:317-324, 2000
21. 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 52:339-350, 2002
22. 18F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: A prospective study. J Clin Oncol 19:111-118, 2001
23. Yorke ED, Jackson A, Rosenweig KE, et al: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329-339, 2002
24. Graham MV, Purdy JA, Emami B, et al: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323-329, 1999
25. Schmuecking M, Baum RP, Bonnet R, et al: F-18 FDG PET and its potential in therapeutic management and 3-D radiation treatment planning of non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 54(S):33
26. Beitler JJ: Unsubstantiated conclusions can impede progress in lung cancer. Int J Radiat Oncol Biol Phys 46:1337, 2000
27. 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51:923-931, 2001
28. Marks LB, Spencer DP, Sherouse GW, et al: The role of three-dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. Int J Radiat Oncol Biol Phys 33:65-75, 1995
29. Munley MT, Marks LB, Scarfone C, et al: Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23:105-114, 1999
30. Seppenwoolde Y, Engelsman M, De Jaeger K, et al: Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol 63:165-177, 2002
31. Scifter T, Hoffman JM, Hanson MW, et al: Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist 17:509, 1993
32. Thornton AF, Sandler HM, Ten Haken RK, et al: The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys 24:767-775, 1992
33. Gross MW, Weber WA, Feldmann HJ, et al: The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41:989-995, 1998
34. Pardo FS, Aronen HJ, Kennedy D, et al: Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys 30:663-669, 1994
35. Levivier M, Wikier D, Goldman S, et al: Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: Early experience with brain tumors. J Neurosurg 93(S):233-238, 2000.
36. 68Ga) EDTA in supratentorial tumors. J Comput Assist Tomograph 9:683-689, 1985
37. Kaschten B, Stevenaert A, Sadzot B, et al: Preoperative evaluation of 54 gliomas by PET with fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778-785, 1998
38. 11C) methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43-52, 2000
39. Hamilton RJ, Sweeney PJ, Pelizzari CA, et al: Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys 37:181-188, 1997
40. Grosu AL, Weber W, Feldmann HJ, et al: First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 47:517-526, 2000
41. Grosu AL, Feldmann HJ, Dick S, et al: Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54:842-854, 2002
42. McGuirt WF, Greven KM, Keyes JW, et al: Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 104:274-278, 1995
43. McGuirt WF, Williams D, Keyes JW, et al: A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 105:373-375, 1995
44. 18Fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinoma. J Nucl Med 36:1747-1757, 1995
45. McGuirt WF, Keyes JW, Greven KW, et al: Preoperative identification of benign versus malignant parotid masses: A comparative study including positron emission tomography. Laryngoscope 105:579-584, 1995
46. 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53:1051-1057, 2002
47. Daisne J, Duprez T, Weynant B, et al: Impact of image coregistration with computed tomography (CT), magnetic resonance (MR) and positron emission tomography with fluorodeoxyglucose (FDG-PET) on delineation of GTV's in oropharyngeal, laryngeal and hypopharyngeal tumors. Int J Radiat Oncol Biol Phys 54(S):15
48. Chao KSC, Bosch WR, Mutic S, et al: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49:1171-1182, 2001
49. Aassar OS, Fishbein N, Caputo GR, et al: Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology 210:177-181, 1999
50. Jungehulsing M, Scheidhauer K, Pietrzyk U, et al: Detection of unknown primary with fluoro-deoxy-glucose positron emission tomography. Ann Otol Rhinol Laryngol 108:623-626, 1999
51. Grigsby PW, Siegel BA, Dehdashti F, et al: Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19:3745-3749, 2001
52. Miller TR, Grigsby PW: Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 53:353-359, 2002
53. Paul R: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 28:288, 1987
54. Valk PE, Pounds TR, Tesar RD, et al: Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23:737-743, 1996